SCA
AIMT

Secor Capital Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Secor Capital Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-40,377
Closed -$1.09M – 623
2018
Q2 		$1.09M Sell
40,377
-13,362
-25% -$409K 0.09% 291
2018
Q1 		$1.71M Buy
+53,739
New +$1.89M 0.14% 232
2017
Q3 		– Sell
-96,619
Closed -$1.99M – 581
2017
Q2 		$1.99M Buy
+96,619
New +$1.84M 0.18% 185

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Secor Capital Advisors's AIMT Position: Q3 2018 in Review

Secor Capital Advisors sold out of Aimmune Therapeutics (AIMT) in Q3 2018, closing a stake of 40,377 shares — an estimated $1.09M sold.

Secor Capital Advisors first reported a position in AIMT in Q2 2017 and held it in 3 quarters. The position peaked at $1.99M in Q2 2017. 142 funds tracked by Wall St. Rank hold AIMT as of Q3 2018.

  • Secor Capital Advisors reported no remaining Aimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Secor Capital Advisors sold 40,377 Aimmune Therapeutics shares in Q3 2018, an estimated $1.09M.
  • Secor Capital Advisors first reported a position in Aimmune Therapeutics in Q2 2017 and held it in 3 quarters.
  • Secor Capital Advisors's Aimmune Therapeutics position peaked at $1.99M in Q2 2017.
  • 142 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2018.

Based on Secor Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.